COMMUNIQUÉS West-GlobeNewswire

Canada Diagnostic Centres, a Novacap Portfolio Company, Announces Acquisition of Shift Imaging
06/07/2026
CALGARY, Alberta, July 06, 2026 (GLOBE NEWSWIRE) -- Canada Diagnostic Centres ("CDC"), a Novacap portfolio company and a leading Canadian community-based diagnostic imaging provider, today announced the acquisition of [...]
Fate Therapeutics to Present Preliminary Clinical Data of FT819 Off-the-Shelf CAR T-Cell Product Candidate for Systemic Sclerosis at the ISSCR 2026 Annual Meeting
06/07/2026
SAN DIEGO, July 06, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent stem cell (iPSC)- [...]
PharmAla Completes GMP Manufacturing of Drug Substance components for ALA-002 Provides Corporate Update Regarding ALA-002 Asset
06/07/2026
TORONTO, July 06, 2026 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (CSE: MDMA)(OTCQB: MDXXF) , a biotechnology company focused on the research, development, and manufacturing of LaNeo™ MDMA and novel derivatives [...]
BiomX: Subsidiary Zorronet Commences Installation and Operation of AI-Powered Detection Systems Under Israel Railways Agreement
06/07/2026
NETANYA, Israel, July 06, 2026 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), announced today following its April 16, 2026 announcement that its wholly-owned subsidiary Zorronet has [...]
Correction: Inspire Medical Systems, Inc. to Report Second Quarter 2026 Financial Results on August 3, 2026
06/07/2026
MINNEAPOLIS, July 06, 2026 (GLOBE NEWSWIRE) -- This press release corrects the earnings release date included in the earlier version issued on July 6, 2026. No other information has changed. Inspire Medical Systems, Inc [...]
LENZ Therapeutics Announces Launch of New Telehealth Prescribing Option to Accelerate Patient Access to VIZZ® for the Treatment of Presbyopia
06/07/2026
VIZZ is now available for those who qualify through a convenient telehealth platform in addition to existing access through eye care professionals Telehealth offers patients the convenience of an integrated online [...]
Catheter Precision, Inc. Announces Issuance of Two Key Patents
06/07/2026
New Intellectual Property Covers VIVO Technology and Cardionomix Heart Failure Technology FORT MILL, SC, July 06, 2026 (GLOBE NEWSWIRE) -- Catheter Precision Inc., (VTAK: NYSE/American), a US based medical device [...]
GuideAI Health Appoints Renowned Interventional Radiologist Dr. James Benenati to Advisory Board Following FDA 510(k) Clearance of VAOT
06/07/2026
Leading Vascular Specialist and Penumbra Chief Medical Officer Joins GuideAI to Help Advance Its Recently FDA-Cleared VAOT Triage Software BOSTON, July 06, 2026 (GLOBE NEWSWIRE) -- GuideAI Health Corp. (Cboe CA: GDAI [...]
CervoMed Showcases Leadership in Advancing the Treatment and Care of Dementia with Lewy Bodies at the Alzheimer's Association International Conference (AAIC) 2026
06/07/2026
Latest findings on neflamapimod to be featured in presentations demonstrating its impact on dementia with Lewy bodies (DLB) disease progression, biomarkers of neurodegeneration, and basal forebrain atrophy, as well as [...]
Opus Genetics Announces FDA Alignment on Phase 3 Registrational Trial Design for OPGx-LCA5 in LCA5-Associated Inherited Retinal Disease
06/07/2026
Successful Type B RDEP Meeting confirms FDA alignment on pivotal Phase 3 study design FDA indicates Opus Genetics may submit a BLA based on 6-month efficacy data, with 12-month durability data provided during review [...]
AtaiBeckley Doses Last Patient in VLS-01 Phase 2b TRD Study; Plans Phase 3 in Major Depressive Disorder
06/07/2026
156 patients randomized in multi-center, double-blind, placebo-controlled Phase 2b Elumina trial; topline data anticipated in Q4 2026 (ClinicalTrials.gov: NCT06524830 ) AtaiBeckley plans to advance VLS-01 into major [...]
Pharvaris Announces FDA Acceptance of New Drug Application for Deucrictibant IR for On-Demand Treatment of Hereditary Angioedema Attacks
06/07/2026
If approved, deucrictibant will be the first oral bradykinin B2 receptor antagonist to treat HAE attacks NDA includes positive data from successful clinical program demonstrating rapid relief and sustained response to [...]
Immuron Advances IMM-529 (Clostridioides difficile infection) Partnering Strategy
06/07/2026
Key Points Immuron Engages Pullan Consulting to Advance IMM-529 Partnering Strategy Immuron is seeking a partner to support clinical development through regulatory approval and commercialization Immuron has U.S. Food [...]
Invivyd Announces Receipt of Twelve Months’ Advanced Notice of Emergency Use Authorization (EUA) Termination for PEMGARDA® and Provides an Update on Next Steps with the U.S. FDA
06/07/2026
U.S. Department of Health and Human Services (HHS) announced advanced Notice of Termination of the COVID-19 EUA declaration, effective June 29, 2027 Consequently, Invivyd received from the U.S. Food and Drug [...]
Nephros Announces Inclusion in the Russell Microcap® Index
06/07/2026
SOUTH ORANGE, N.J., July 06, 2026 (GLOBE NEWSWIRE) -- Nephros, Inc. (Nasdaq: NEPH), a leading water technology company providing filtration solutions to the medical and commercial markets, today announced that the [...]
Can-Fite Achieves Key Pivotal Phase 3 Psoriasis Milestone with Completion of Patient Enrolment for the Interim Analysis: Data Expected Q4 2026/Q1 2027
06/07/2026
Interim analysis to be conducted under an FDA- and EMA-agreed protocol Ramat Gan, Israel, July 06, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a clinical-stage biotechnology [...]
Grey Matters Takes Delivery of the First Brain Dedicated PET Scanning System for its Flagship NovaScan Neuroimaging Clinic in Florida
06/07/2026
VANCOUVER, British Columbia, July 06, 2026 (GLOBE NEWSWIRE) -- Grey Matters Health Inc. (the “Company” or “Grey Matters”) (CSE: GREY) (FRANKFURT: AGW0) (OTC: AGNPF), a Canadian healthcare company, is pleased to announce [...]
Novo Nordisk A/S - share repurchase programme
06/07/2026
Bagsværd, Denmark, 6 July 2026 – On 6 May 2026, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) [...]
Pluristyx Inc. Secures Initial Close of Series A Priced Round with Multinational Fortune 500 Company; Round to Remain Open for Syndicate Partners Until September 2nd
06/07/2026
Led by the venture arm of a strategic partner, proceeds will support inventory build and commercialization of proprietary polyclonal stem cells engineered with safety and universality features to support diverse [...]

Pages